Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Jennifer F, Lai"'
Autor:
Adrian A. Franke, Xingnan Li, Thaddeus A. Herzog, Yvette C. Paulino, Grazyna Badowski, Lynne R. Wilkens, Jennifer F. Lai
Publikováno v:
Drug Testing and Analysis. 15:58-65
The Betel Nut Intervention Trial (BENIT) is the first known randomized controlled intervention trial designed to help minority Pacific Islanders in Guam and Saipan quit chewing the carcinogenic Areca catechu nut (AN). We report the BENIT's saliva bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5c803ef83e15ea1f84c6012adf6b58a
https://doi.org/10.1002/dta.3364
https://doi.org/10.1002/dta.3364
Publikováno v:
Anal Bioanal Chem
Aminomethylphosphonic acid (AMPA) is the main metabolite of glyphosate (GLYP) and phosphonic acids in detergents. GLYP is a synthetic herbicide frequently used worldwide alone or together with its analog glufosinate (GLUF). The general public can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20a9657b534437fbb215f1caa26e51b7
https://doi.org/10.1007/s00216-020-02966-1
https://doi.org/10.1007/s00216-020-02966-1
Publikováno v:
Subst Use Misuse
BACKGROUND: Areca nut (AN) chewing causes oral cancer. AN cessation programs are the most effective approach to reduce AN chewing induced cancers but require biomarkers to determine program compliance and success. OBJECTIVES: To explore chemical mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f8520b845b3aea4fa74d3bbf08dabc2
https://doi.org/10.1080/10826084.2019.1630442
https://doi.org/10.1080/10826084.2019.1630442
Publikováno v:
Environ Pollut
Breast cancer is the most commonly diagnosed female cancer and the second leading cause of death in women in the US, including Hawaii. Accumulating evidence suggests that aminomethylphosphonic acid (AMPA), the primary metabolite of the herbicide glyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0562d435c23ddb83edbc4bbb775d3f8e
https://pubmed.ncbi.nlm.nih.gov/33714786
https://pubmed.ncbi.nlm.nih.gov/33714786
Publikováno v:
Drug testing and analysisREFERENCES. 12(6)
Native circulating oxytocin (OT) levels in non-pregnant/non-lactating/non-medicated humans are very low (≤ 8 pg/mL). The lower limit of detection (LLOD) of our previous liquid chromatography mass spectrometry (LC-MS) method (10-25 pg/mL) precluded
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f51356151b0cb7aef63f9f0d6fa1a51
https://pubmed.ncbi.nlm.nih.gov/32100408
https://pubmed.ncbi.nlm.nih.gov/32100408
Publikováno v:
The FASEB Journal. 33
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c16798e3065ee53b12732a21fd755a8d
https://doi.org/10.1096/fasebj.2019.33.1_supplement.636.6
https://doi.org/10.1096/fasebj.2019.33.1_supplement.636.6
Publikováno v:
Drug Test Anal
Background Areca nut (AN) chewing is carcinogenic and biomarkers reflecting it are urgently needed to determine the effectiveness of emergent cessation programs. Buccal cells (BCs) may serve as an ideal matrix to measure such biomarkers; however, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5038b815ae6dbb7471371ea5b76e597
https://pubmed.ncbi.nlm.nih.gov/30845375
https://pubmed.ncbi.nlm.nih.gov/30845375
Publikováno v:
The FASEB Journal. 34:1-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d282cf04688a43b7de432e4c38d77ba1
https://doi.org/10.1096/fasebj.2020.34.s1.00259
https://doi.org/10.1096/fasebj.2020.34.s1.00259
Publikováno v:
The FASEB Journal. 32
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d69bcbda5c148399b6dd455f8c4cee6
https://doi.org/10.1096/fasebj.2018.32.1_supplement.800.10
https://doi.org/10.1096/fasebj.2018.32.1_supplement.800.10
Autor:
Leora Horn, Nikoletta L. Kallinteris, David R. Spigel, Ramon Palmero, Joseph Shan, Athanasios Kotsakis, Min Tang, D. Ghizdavescu, David E. Gerber, P. Bidoli, György Losonczy, W-C Su, Hervé Lena, Paul Germonpré, Igor Bondarenko, Martin Reck, Rachel E. Sanborn, Jennifer F. Lai, M. Boyer, Ronald B. Natale, Kwan Park
Background: Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an antitumor immune response. This phase III trial determined the efficacy of bavituximab combined with docetaxel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e7b58c1ff58194f0d3dbc26722f5ebc
http://hdl.handle.net/10281/260656
http://hdl.handle.net/10281/260656
